Praesidian Capital successfully exited its investment in Biologos Holdings, a provider of sterile-filtered biological products, realizing notable growth since its initial investment in 2015.

Information on the Target

Biologos Holdings, LLC (“Biologos”) is a distinguished provider of sterile-filtered biological products specifically designed for veterinary, pharmaceutical, and medical research applications. Established to meet the growing demand for high-quality biological materials, Biologos has positioned itself as a trusted partner in this niche industry. Its innovative product offerings cater to a diverse range of clients, ensuring compliance with the highest quality standards.

Since its inception, Biologos has demonstrated a steadfast commitment to excellence in product development and customer service, which has been instrumental in fostering strong relationships within the scientific and medical research communities. This dedication has not only enhanced its reputation but has also fueled its growth over the past several years.

Industry Overview in the Target’s Specific Country

The biological products industry in the United States is experiencing significant growth, driven by advancements in medical research and an increasing focus on veterinary health